KaloBioS Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its proprietary platform technology to develop first or best-in-class human antibody therapeutics. It currently has two programs that have completed Phase 1 trials and are entering Phase 1/2 trials; KB001 and KB002. KB001, a Humaneered™, high affinity antibody fragment that KaloBios is developing as an anti-infective for Pseudomonas aeruginosa infections, recently initiated a Phase 1/2 trial in patients with cystic fibrosis and plans to start a trial in intensive care patients on a ventilator in the first half of 2008. KB002 is an anti-inflammatory in a Phase 1/2 trial for rheumatoid arthritis and just recently initiated a trial in patients with persistent asthma. The company’s technology, “Humaneering™”, offers advantages over other methods of human antibody creation in terms of immunogenicity, potency, and manufacturing yields. The company focuses on partnering its clinical-stage programs and also grants limited access to its Humaneering™ platform to select partners.

KaloBios was formed in 2001 and merged in 2004 with Celscia. Since the company’s founding, it has raised a total of $48 million in three rounds of venture funding with the major shareholders being MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, and Lehman Brothers. The company is headquartered in Palo Alto, CA and has approximately 35 employees.

Mission

Values